- 1
Pandolfino J E, El Serag H B, Zhang Q. et al .
Obesity: a challenge to esophagogastric junction integrity.
Gastroenterology.
2006;
130
639-649
- 2
Wu J, Mui W L, Chan W. et al .
Obesity is associated with increased transient lower esophageal sphincter relaxation.
Gastroenterology.
2007;
132
A121
- 3
Beaumont H, de Jong J W, Bennink . et al .
Scintigraphic imaging of esophageal shortening and the acid pocket in humans.
Gastroenterology.
2007;
132
A121
- 4
Schey R, Dickman R M, Parthasarathy S. et al .
Sleep deprivation is hyperalgesic in patients with gastroesophageal reflux disease
(GERD).
Gastroenterology.
2007;
132
A122
- 5
Strugala V, McGlashan J A, Watson A G. et al .
Evaluation of a non-invasive dipstick test for the diagnosis of extra-oesophageal
reflux: results of a pilot study.
Gastroenterology.
2007;
132
A99
- 6
Fiocca R, Fernström P, Franzen S. et al .
Can pathologists agree in the assessment of microscopic esophagitis?.
Gastroenterology.
2007;
132
A281
- 7
Kara M A, Peters F P, Rosmolen W D. et al .
High-resolution endoscopy plus chromoendoscopy or narrow-band imaging in Barrett’s
esophagus: a prospective randomized crossover study.
Endoscopy.
2005;
37
929-936
- 8
Sharma P, Bansal A, Mathur S. et al .
The utility of a novel narrow band imaging endoscopy system in patients with Barrett’s
esophagus.
Gastrointest Endosc.
2006;
64
167-175
- 9
Sharma P, Wani S B, Rastogi A. et al .
Effect of acid suppressive therapy on narrow-band imaging (NBI) findings in gastroesophageal
reflux disease (GERD) patients.
Gastroenterology.
2007;
132
A98
- 10
Fox M R, Canavan R, Anggiansah A. et al .
What is the optimal duration of oesophageal pH measurement and symptom assessment?
A prospective study using 96-hr BRAVO recordings.
Gastroenterology.
2007;
132
A99
- 11
Gilles M D, Ayers G D, Vaezi M F.
96 hours no better than 24 hours in atypical GERD.
Gastroenterology.
2007;
132
A99
- 12
Zerbib F, Roman S, Ropert A. et al .
Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients
off and on therapy.
Am J Gastroenterol.
2006;
101
1956-1963
- 13
Zentilin P, Della Casa D, Fanucchi M. et al .
24-hour ambulatory intraluminal pH-impedance in patients with non-erosive reflux disease
(NERD).
Gastroenterology.
2007;
132
A140
- 14
Wu J, Ching J, Au K. et al .
Clinical course of patients with non-erosive gastroeophageal reflux disease (NERD)
on step-down acid suppressive therapy: a prospective cohort study.
Gastroenterology.
2007;
132
A139
- 15
Iuga L M, Orvidas L J, Dierkhising R A. et al .
Which supraesophageal reflux symptoms reliably respond to PPI therapy? Results from
a randomized, double-blind, placebo-controlled trial (RCT).
Gastroenterology.
2007;
132
A99
- 16
Lundell L R, Miettinen P, Myrvold H E. et al .
Anti-reflux surgery compared with maintenance omeprazole for reflux esophagitis: results
after 12 years.
Gastroenterology.
2007;
132
A107
- 17
Targownik L E, Laheij R J, Metge C. et al .
Proton pump inhibitor use is associated with an increased risk of severe community-acquired
infections.
Gastroenterology.
2007;
132
A189
- 18
Estborn L, Joelson S.
Respiratory tract infections with acid-suppressive therapy: a retrospective analysis
of 31 comparative clinical studies in esomeprazole.
Gastroenterology.
2007;
132
A159
- 19
Falk G W, Fennerty M B, Rothstein R I.
AGA Institute technical review on the use of endoscopic therapy for gastroesophageal
reflux disease.
Gastroenterology.
2006;
131
1315-1336
- 20
Pleskow D, Rothstein R, Kozarek R. et al .
Endoscopic full-thickness plication for the treatment of GERD: long-term multicenter
results.
Surg Endosc.
2007;
21
439-444
- 21
Dundon J M, Davis S, Hazey J W. et al .
Radiofrequency energy delivery to the lower esophageal sphincter (Stretta) does not
provide long-term symptom control.
Gastrointest Endosc.
2007;
65
AB129
- 22
Kuan-Hao C, Mukaisho K I, Araki Y. et al .
High fat intake plays a crucial role in the development of Barrett’s esophagus and
esophageal adenocarcinoma through elevated bile acids in duodenal contents reflux.
Gastroenterology.
2007;
132
A260
- 23
Menke V, Capello A, Kusters J G. et al .
Th1 immune status in patients is associated with an increased risk for Barrett’s esophagus.
Gastroenterology.
2007;
132
A76
- 24
Razvi M, Dar A, Washington K. et al .
Transcriptional hotspots in Barrett’s-related adenocarcinomas.
Gastroenterology.
2007;
132
A133
- 25
Buttar N, DeMars C, Madhavan M. et al .
Role of KLF in neoplastic progression in Barrett’s esophagus.
Gastroenterology.
2007;
132
A76
- 26
Wong A, Lovat L L, Burnham R. et al .
Large-scale prospective study reveals novel risk factors for Barrett’s oesophagus.
Gastroenterology.
2007;
132
A254
- 27
Modiano N, Shahnia S, Gerson L B.
Development of Barrett’s esophagus after erosive esophagitis.
Gastrointest Endosc.
2007;
65
AB142
- 28
Meining A, Pohl H, Becker V. et al .
Miniprobe-based confocal fluorescence microscopy for detection of focal malignancy
in Barrett’s esophagus.
Gastrointest Endosc.
2007;
65
AB138
- 29
Meining A, Saur D, Bajbouj M. et al .
Real-time in-vivo histopathology for detection of neoplasia using a portable, confocal
miniprobe: a blinded analysis.
Gastroenterology.
2007;
132
A97
- 30
Gatenby P A, Ramus J A, Caygill C P. et al .
The outcome of low-grade dysplasia in Barrett’s columnar-lined esophagus: a large
cohort study from the UK national Barrett’s oesophagus registry.
Gastrointest Endosc.
2007;
65
AB133
- 31
Mackenzie G, Yong M, Clark B. et al .
Elastic scattering spectroscopy to generate an image of patient risk in Barrett’s
esophagus.
Gastroenterology.
2007;
132
A96
- 32
Pech O, Manner H, Petrone M C. et al .
One-step chromoendoscopy and structure enhancement using balsamic vinegar for screening
of Barrett’s esophagus.
Gastrointest Endosc.
2007;
65
AB146
- 33
Kiesslich R, Hoffman A, Vieth M. et al .
80 mg esomeprazole daily over 6 months does not lead to a significant regression of
Barrett’s esophagus: results from a prospective randomized trial.
Gastrointest Endosc.
2007;
65
AB151
- 34
Pech O, Behrens A, Nachbar L. et al .
Long-term results and risk factor analysis for recurrence in 349 patients with high-grade
dysplasia and mucosal adenocarcinoma in Barrett’s esophagus.
Gastrointest Endosc.
2007;
65
AB99
- 35
Manner H, May A, Pech O. et al .
Early Barrett’s carcinoma with minimal submucosal involvement: long-term results of
endoscopic resection with a curative intent.
Gastrointest Endosc.
2007;
65
AB136
- 36
Wang K K, Buttar N, Prasad G A. et al .
Endoscopic mucosal resection in Barrett’s esophagus: predictors of success and complications.
Gastroenterology.
2007;
132
A64
- 37
Prasad G A, Wang K K, Halling K C. et al .
Biomarkers in the therapy of Barrett’s esophagus with high-grade dysplasia.
Gastroenterology.
2007;
132
A64
- 38
Pouw R E, Gondrie J J, Sondermeijer C. et al .
Novel combined therapy for Barrett’s esophagus containing high-grade dysplasia: endoscopic
mucosal resection followed by circumferential and focal ablation using the HALO system.
Gastrointest Endosc.
2007;
65
AB111
- 39
Hernandez J C, Tsai F, Reicher S. et al .
Frequency of buried Barrett’s metaplasia after BÂRRX ablation for intestinal metaplasia
with or without dysplasia.
Gastrointest Endosc.
2007;
65
AB111
- 40
Mashimo H, Chen Y, Huang S W. et al .
Endoscopic coherence tomography reveals Barrett’s underneath squamous neo-epithlium
after radiofrequency ablation.
Gastroenterology.
2007;
132
A96
- 41
Dumot J A, Vargo J J, Zuccaro G. et al .
Preliminary results of cryotherapy ablation for esophageal high-grade dysplasia (HGD)
or intra-mucosal cancer (IMC) in high-risk non-surgical patients.
Gastrointest Endosc.
2007;
65
AB110
H. Louis, MD, PhD
Department of Gastroenterology and Hepatopancreatology
Erasme Hospital
Route de Lennik 808
B-1070 Brussels
Belgium
Fax: +32-2-555-46-97
eMail: hlouis@ulb.ac.be
